Plugging up ear care
COLD SPRING HARBOR, N.Y. —Cirrus Healthcare Products recently announced the launch of Tinnitex, one of the first ear care products designed to help relieve tinnitus, otherwise known as ringing in the ears. The new product is scheduled to ship in the first half of 2011.
According to the Journal of Clinical Nursing, more than 50 million Americans suffer from tinnitus. Today’s remedies include eardrops and nutritional supplements. Employing infusion technology, Cirrus has developed the Tinnitex earplug so that it delivers ingredients that help relieve ringing in the ears transdermally. The soft silicone earplugs are infused with aloe vera, vitamin B12, zinc and ginkgo biloba. The product should be a welcome addition to the company’s EarPlanes, which generated $2.5 million in sales for the 52 weeks ended Sept. 5 across food, drug and mass (excluding Walmart), according to SymphonyIRI Group data. Overall, sales of ear care products were up 7.6% to $44.4 million for the same period.
Diabetes prevalence among Americans may increase to 33%, CDC study finds
ATLANTA The rate of diabetes among Americans is on an upswing and likely will reach epic proportions by 2050, costing the government millions.
Anew study by the Centers for Disease Control and Prevention and published in Population Health Metrics found that annual diagnosed diabetes incidence (new cases) will increase from about eight cases per 1,000 people in 2008 to about 15 in 2050. The authors also projected that — assuming low incidence and relatively high diabetes mortality — total diabetes prevalence (diagnosed and undiagnosed cases) is projected to increase from 14% in 2010 to 21% of the U.S. adult population by 2050, but noted that if recent increases in diabetes incidence continue and diabetes mortality is relatively low, prevalence will increase to 33% by 2050.
In 2007, diabetes cost the United States in excess of $174 billion. With the increased prevalence of diabetes in the country, the CDC suggested that the projected loss in quality of life and the projected costs of providing health care could be significant, as the healthcare costs of a person with diagnosed diabetes are approximately 2.3 times higher than nondiabetics, the authors noted.
"These are alarming numbers that show how critical it is to change the course of Type 2 diabetes," said Ann Albright, director of CDC’s division of diabetes translation. "Successful programs to improve lifestyle choices on healthy eating and physical activity must be made more widely available, because the stakes are too high and the personal toll too devastating to fail."
The authors also noted that intervention can reduce, but not eliminate, increases in diabetes prevalence.
New Lo Loestrin Fe gets FDA approval
ARDEE, Ireland The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug maker said Friday.
The company said it plans to launch Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) early next year. The company said the contraceptive contains the lowest dosage of estrogen — 10 micrograms — of any oral contraceptive currently available in the U.S. market.
“We are excited about the approval of Lo Loestrin Fe, which complements our women’s healthcare franchise and expands the product offerings in our branded oral contraceptive portfolio,” president and CEO Roger Boissonneault said in a statement.